Trials / Completed
CompletedNCT00451516
St. John's Wort And Kava In The Treatment Of Major Depressive Disorder With Comorbid Anxiety
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- Sponsor
- The University of Queensland · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
SJW has the greatest evidence of herbal medicine efficacy in treating MDD. In treating anxiety, kava has the greatest evidence of efficacy. As comorbidity of MDD and anxiety commonly occurs, it is conceivable that a combination of an established antidepressant agent such as SJW and an established anxiolytic agent such as kava may effectively treat MDD presenting with comorbid anxiety. It is possible that a beneficial synergistic effect may also occur between SJW and kava, improving the treatment outcomes in MDD with comorbid anxiety, than by the individual substances alone. Determination of this is not addressed in this study due to limitations of time and resources. The determination of the strength of the SJW-kava combination will be ascertained by comparing similar trials using SJW and kava mono-therapy in addressing MDD and GAD. The hypothesis is that a combination of SJW and kava will reduce MDD occurring with comorbid anxiety more than placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Herbal medicine (St. John's wort and Kava) |
Timeline
- Start date
- 2007-03-01
- Primary completion
- 2007-10-01
- Completion
- 2007-10-01
- First posted
- 2007-03-23
- Last updated
- 2008-05-19
Locations
1 site across 1 country: Australia
Source: ClinicalTrials.gov record NCT00451516. Inclusion in this directory is not an endorsement.